Clinical trial • Phase III • Gastroenterology

Potassium chloride; Sodium chloride; Calcium chloride dihydrate; Sodium lactate for Acute pancreatitis

Phase III trial of Potassium chloride; Sodium chloride; Calcium chloride dihydrate; Sodium lactate for Acute pancreatitis.

Overview

Trial Therapeutic Area
Gastroenterology
Trial Disease
Acute pancreatitis
Trial Stage
Phase III
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
08-03-2024
First CTIS Authorization Date
17-05-2024

Trial design

Randomised, open-label, two active comparator arms: ringer's lactate solution (ringer laktát hartmann "baxter" solution for infusion) versus normal saline (nátrium-klorid eurolife 0,9% solution for infusion). dose/schedule not specified in the record.-controlled Phase III trial across 1 site in Hungary.

Randomised
Yes
Open Label
Yes
Comparator
Two active comparator arms: Ringer's lactate solution (Ringer Laktát Hartmann "Baxter" solution for infusion) versus Normal saline (Nátrium-klorid EUROLIFE 0,9% solution for infusion). Dose/schedule not specified in the record.
Target Sample Size
720
Trial Duration For Participant
7

Eligibility

Recruits 720 No vulnerable populations selected; informed consent is required ("Signature of informed consent"). No assent procedures or specific provisions for minors described; trial inclusion starts at 18 years of age..

Vulnerable Population
No vulnerable populations selected; informed consent is required ("Signature of informed consent"). No assent procedures or specific provisions for minors described; trial inclusion starts at 18 years of age.

Inclusion criteria

  • {"criterion_text":"- 18 years of age"}
  • {"criterion_text":"- Diagnosis of acute pancreatitis according to the revision of the Atlanta classification (Banks et al, Gut 2013), which requires at least two of the following three criteria: A) typical abdominal pain, B) increase in serum amylase or lipase levels higher than three times the upper limit of normality, and C) signs of acute pancreatitis in imaging"}
  • {"criterion_text":"- Signature of informed consent"}

Exclusion criteria

  • {"criterion_text":"- New York Heart Association class II heart failure (slight limitation of physical activity; fatigue, palpitations, or dyspnea with ordinal physical activity) or worse, or ejection fraction <50% in the last echocardiography"}
  • {"criterion_text":"- Chronic pancreatitis defined by a Wirsung duct ≥4mm and/or pancreatic calcifications"}
  • {"criterion_text":"- More than 1 previous episode of acute pancreatitis (only 2 episodes of acute pancreatitis are allowed, one of them the present episode)"}
  • {"criterion_text":"- Decompensated cirrhosis (Child’s class B or C)"}
  • {"criterion_text":"- Hyper or hyponatremia (<135 or >145 mEq/L)"}
  • {"criterion_text":"- Hyperkalemia (>5 mEq/L)"}
  • {"criterion_text":"- Hypercalcemia (albumin or protein-corrected calcium >10.5 mg/dL or 2.62 mmol/L)"}
  • {"criterion_text":"- Criteria for moderately severe or severe acute pancreatitis (revision of the Atlanta classification, Banks et al, Gut 2013) at recruitment: any of the following: A) presence of creatinine ≥1.9 mg/dL or ≥170 mmol/l, B) PaO2/FiO2≤300, C) systolic blood pressure <90 mmHg despite initial fluid resuscitation, D) presence of local complications (acute peripancreatic fluid collections, acute necrotic collection, pseudocyst, walled-off necrosis, gastric outlet dysfunction, splenic or portal vein thrombosis, or colonic necrosis), E) exacerbation of previous comorbidity such as coronary artery disease or chronic lung disease, precipitated by the acute pancreatitis"}
  • {"criterion_text":"- Signs of volume overload or heart failure at recruitment (peripheral edema, pulmonary rales, or increased jugular ingurgitation at 45º)"}
  • {"criterion_text":"- Time from pain onset to arrival to emergency room >24 h"}
  • {"criterion_text":"- Time from confirmation of pancreatitis to randomization >8 h"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- The primary outcome will be moderately severe to severe AP, according to the revision of the Atlanta classification. The primary safety outcome will be a composite variable involving any of the following: fluid overload, acute kidney injury, hyperkalemia, hypercalcemia, or acidosis.","definition_or_measurement_approach":"Severity classified using the revision of the Atlanta classification (Banks et al, Gut 2013). Safety measured as a composite of specified events: fluid overload, acute kidney injury, hyperkalemia, hypercalcemia, or acidosis."}

Recruitment

Planned Sample Size
720
Recruitment Window Months
13
Consent Approach
Informed consent required: "Signature of informed consent". Participants (adult, ≥18 years) provide written consent. No information on assent or age-specific consent forms or languages provided.

Geography

Total Number Of Sites
1
Total Number Of Participants
720

Hungary

Earliest CTIS Part Ii Submission Date
29-04-2024
Latest Decision Or Authorization Date
17-05-2024
Processing Time Days
18
Number Of Sites
1
Number Of Participants
720

Sites

Site Name
Semmelweis University
Department Name
Department for Pancreatic Disorders
Principal Investigator Name
Péter Hegyi
Principal Investigator Email
hegyi.peter@semmelweis.hu
Contact Person Name
Péter Hegyi
Contact Person Email
hegyi.peter@semmelweis.hu
Number Of Participants
720

Sponsor

Primary sponsor

Full Name
Semmelweis University
Organisation Type
Educational Institution
Country Of Registered Address
Hungary

Investigational products

Investigational Product Name
Ringer Laktát Hartmann „Baxter” oldatos infúzió
Active Substance
Potassium chloride; Sodium chloride; Calcium chloride dihydrate; Sodium lactate
Modality
Small molecule
Routes Of Administration
Infusion
Route
Infusion
Authorisation Status
Authorised (marketing authorisation: OGYI-T-9472/03, HU)
Maximum Dose
Max daily dose: 4000 ml; Max total dose: 28000 ml
Investigational Product Name
Nátrium-klorid EUROLIFE 0,9% oldatos infúzió
Active Substance
Sodium chloride
Modality
Small molecule
Routes Of Administration
Infusion
Route
Infusion
Authorisation Status
Authorised (marketing authorisation: OGYI-T-24135/01, HU)
Maximum Dose
Max daily dose: 4000 ml; Max total dose: 28000 ml

Related trials

Other published trials that may interest you.